Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial
Savino Bruno(Humanitas University), G. Pinzello, Mario Camozzi(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), V. Di Marco(University of Palermo), M. Vinci(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Danilo Di Bona(Istituto di Biomedicina e di Immunologia Molecolare Alberto Monroy), Mario U. Mondelli(University of Pavia), Maria Grazia Rumi(University of Milan), Antonio Craxı̀(University of Palermo), Calogero Cammà(Department of Health), Massimo Colombo(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Chiara Rebucci(University of Pavia)
Cited by 95
Related Papers
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
|Journal of Hepatology|2001|4.1k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
|The Lancet. Gastroenterology & hepatology|2022|664
Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.
|Journal of Clinical Investigation|1996|661